Bellevue Group AG Q3 2016 Filing

Filed November 10, 2016

Portfolio Value

$553.5B

Holdings

121

Report Date

Q3 2016

Filing Type

13F-HR

All Holdings (121 positions)

#StockSharesValue% PortfolioType
101
Team Health Holdings Inc.
25,000$814.0M0.15%
102
GW Pharmaceuticals PLC
6,000$796.0M0.14%
103
AAC Hldgs Inc
45,000$783.0M0.14%
104
NVROEURNevro Corp.
7,500$783.0M0.14%
105
Kite Pharma, Inc.
14,000$782.0M0.14%
106
EX9Exelixis, Inc.
60,000$767.0M0.14%
107
UTHUnited Therapeutics Corporation
6,300$744.0M0.13%
108
VAREURVarian Medical Systems, Inc.
7,000$697.0M0.13%
109
NVAXNovavax, Inc.
325,000$676.0M0.12%
110
TBPHTheravance Biopharma, Inc.
18,428$668.0M0.12%
111
DVADavita Healthcare Partners, Inc.
10,000$661.0M0.12%
112
Celldex Therapeutics, Inc.
160,000$646.0M0.12%
113
PODDInsulet Corporation
15,000$614.0M0.11%
114
ESPREsperion Therapeutics Inc.
40,000$554.0M0.10%
115
RMEResMed Inc.
8,000$518.0M0.09%
116
PENPenumbra, Inc.
5,000$380.0M0.07%
117
Webmd Health Corp
7,400$368.0M0.07%
118
SGRYSurgery Partners, Inc.
15,000$304.0M0.05%
119
MYGNMyriad Genetics, Inc.
14,000$288.0M0.05%
120
Quorum Health Corp
12,500$78.0M0.01%
121
CLDNEUREiger BioPharmaceuticals, Inc.
3,333$45.0M0.01%
PreviousPage 2 of 2